1. The Economics Driving the Biosimilar IP War The global biosimilar market is not a niche regulatory experiment. It is […]
The Biosimilar Patent Dance and PTAB Playbook: How to Win the Biologic IP War Read Post »
The definitive guide to sildenafil IP strategy, authorized generics, evergreening tactics, and what the Viagra case teaches pharma teams about
The U.S. spent roughly $400 billion on specialty drugs in 2022. A record $9.4 billion of that was clawed back
The Unified Patent Court went live on June 1, 2023. Pharma IP teams and biotech portfolio managers who treated that
The Economics Behind Low-Competition Generic Markets Why Price Decay Makes Niche Sourcing Mandatory Generic drug markets operate on a compression
1. Who This Guide Is For This guide is written for IP counsel, portfolio managers, R&D leads, and institutional investors
AI Drug Patents: The Complete IP Strategy Guide for Pharma and Biotech Read Post »
Executive Summary The global biopharmaceutical sector has entered a decisive inflection point in early 2026, characterized by the convergence of
What Patent Timing Actually Decides A pharmaceutical patent filed on Day 1 of discovery and a patent filed after Phase
The Power of Patience: The Pharma Playbook for Extending Market Exclusivity Read Post »
Atorvastatin lost its primary patent on November 30, 2011. What followed was the most studied loss-of-exclusivity response in pharmaceutical history.
Sign in or create a free account to read this DrugPatentWatch article
